![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
C Pifl, H Drobny, H Reither, O Hornykiewicz and EA Singer
Institute of Biochemical Pharmacology, University of Vienna, Austria.
The effects of amphetamine and cocaine were studied in [3H]-dopamine- loaded and superfused COS-7 cells transfected with either the cDNA of the plasmalemmal dopamine transporter ("DAT cells") or the cDNA of the vesicular amine transporter ("VAT cells"), or with both transporters ("DAT/VAT cells"). Amphetamine (0.01-100 microM, added for 4 min of superfusion) led to a concentration-dependent increase in dopamine release in DAT cells, as well as in DAT/VAT cells. The EC50 of the effect of amphetamine on DAT cells was 1.1 +/- 0.6 microM; the effect on DAT/VAT cells did not reach a plateau in the concentration range tested. With longer exposure to amphetamine, dopamine efflux from DAT cells reached a peak and quickly returned to baseline, in spite of the continued presence of the drug, whereas in DAT/VAT cells and in VAT cells the effect was sustained. Cocaine (up to 100 microM) did not exert any effect of its own in DAT cells or VAT cells but inhibited the amphetamine-induced release of dopamine from DAT cells in a competitive manner. In DAT/VAT cells cocaine and its analogue (-)-2 beta- carbomethoxy-3 beta-(4-fluorophenyl)tropane caused an efflux of dopamine resembling that caused by amphetamine but quantitatively much smaller. The rank order of potency was the same as in uptake experiments [(-)-2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane > cocaine]. The effect of cocaine was mimicked by the reduction of chloride. The results indicate that there is a plasmalemmal component and a vesicular component in the dopamine-releasing action of amphetamine. The releasing action of cocaine is dependent on the existence of a vesicular pool of the neurotransmitter and seems to be linked to inhibition of the plasmalemmal dopamine transporter.
This article has been cited by other articles:
|
|
 |
|
  D. Marazziti, S. Mandillo, C. Di Pietro, E. Golini, R. Matteoni, and G. P. Tocchini-Valentini GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs PNAS, June 5, 2007; 104(23): 9846 - 9851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Escubedo, C. Chipana, M. Perez-Sanchez, J. Camarasa, and D. Pubill Methyllycaconitine Prevents Methamphetamine-Induced Effects in Mouse Striatum: Involvement of {alpha}7 Nicotinic Receptors J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 658 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pifl, G. Nagy, S. Berenyi, A. Kattinger, H. Reither, and S. Antus Pharmacological Characterization of Ecstasy Synthesis Byproducts with Recombinant Human Monoamine Transporters J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 346 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-K. Meinild, H. H. Sitte, and U. Gether Zinc Potentiates an Uncoupled Anion Conductance Associated with the Dopamine Transporter J. Biol. Chem., November 26, 2004; 279(48): 49671 - 49679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Wilhelm, R. A. Johnson, P. G. Lysko, A. J. Eshleman, and A. Janowsky Effects of Methamphetamine and Lobeline on Vesicular Monoamine and Dopamine Transporter-Mediated Dopamine Release in a Cotransfected Model System J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1142 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Larsen, E. A. Fon, T. G. Hastings, R. H. Edwards, and D. Sulzer Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis J. Neurosci., October 15, 2002; 22(20): 8951 - 8960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Scholze, L. Norregaard, E. A. Singer, M. Freissmuth, U. Gether, and H. H. Sitte The Role of Zinc Ions in Reverse Transport Mediated by Monoamine Transporters J. Biol. Chem., June 7, 2002; 277(24): 21505 - 21513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Tremblay, C. A. Naranjo, L. Cardenas, N. Herrmann, and U. E. Busto Probing Brain Reward System Function in Major Depressive Disorder: Altered Response to Dextroamphetamine Arch Gen Psychiatry, May 1, 2002; 59(5): 409 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kantor, G. H. K. Hewlett, Y. H. Park, S. M. Richardson-Burns, M. J. Mellon, and M. E. Gnegy Protein Kinase C and Intracellular Calcium Are Required for Amphetamine-Mediated Dopamine Release via the Norepinephrine Transporter in Undifferentiated PC12 Cells J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1016 - 1024. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. H. Sitte, B. Hiptmair, J. Zwach, C. Pifl, E. A. Singer, and P. Scholze Quantitative Analysis of Inward and Outward Transport Rates in Cells Stably Expressing the Cloned Human Serotonin Transporter: Inconsistencies with the Hypothesis of Facilitated Exchange Diffusion Mol. Pharmacol., April 16, 2001; 59(5): 1129 - 1137. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Brown, G. R. Hanson, and A. E. Fleckenstein Regulation of the Vesicular Monoamine Transporter-2: A Novel Mechanism for Cocaine and Other Psychostimulants J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 762 - 767. [Abstract] [Full Text]
|
|
|
|
|
|
D. K. Miller, P. A. Crooks, L. Teng, J. M. Witkin, P. Munzar, S. R. Goldberg, J. B. Acri, and L. P. Dwoskin Lobeline Inhibits the Neurochemical and Behavioral Effects of Amphetamine J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1023 - 1034. [Abstract] [Full Text]
|
|
|
|
|
|
P. Scholze, J. Zwach, A. Kattinger, C. Pifl, E. A. Singer, and H. H. Sitte Transporter-Mediated Release: A Superfusion Study on Human Embryonic Kidney Cells Stably Expressing the Human Serotonin Transporter J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 870 - 878. [Abstract] [Full Text]
|
|
|
|
|
|
C. Pifl and E. A. Singer Ion Dependence of Carrier-Mediated Release in Dopamine or Norepinephrine Transporter-Transfected Cells Questions the Hypothesis of Facilitated Exchange Diffusion Mol. Pharmacol., November 1, 1999; 56(5): 1047 - 1054. [Abstract] [Full Text]
|
|
|
|
|
|
J. K. Weatherspoon and L. L. Werling Modulation of Amphetamine-Stimulated [3H]Dopamine Release from Rat Pheochromocytoma (PC12) Cells by sigma Type 2 Receptors J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 278 - 284. [Abstract] [Full Text]
|
|
|
|
|
|
F. Fumagalli, R. R. Gainetdinov, Y.-M. Wang, K. J. Valenzano, G. W. Miller, and M. G. Caron Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice J. Neurosci., April 1, 1999; 19(7): 2424 - 2431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Jones, R. R. Gainetdinov, R. M. Wightman, and M. G. Caron Mechanisms of Amphetamine Action Revealed in Mice Lacking the Dopamine Transporter J. Neurosci., March 15, 1998; 18(6): 1979 - 1986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sonders, S.-J. Zhu, N. R. Zahniser, M. P. Kavanaugh, and S. G. Amara Multiple Ionic Conductances of the Human Dopamine Transporter: The Actions of Dopamine and Psychostimulants J. Neurosci., February 1, 1997; 17(3): 960 - 974. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
